Luye Pharma Group Ltd.
🇨🇳China
Clinical Trials
67
Active:1
Completed:44
Trial Phases
4 Phases
Phase 1:51
Phase 2:3
Phase 3:12
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (67 trials with phase data)• Click on a phase to view related trials
Phase 1
51 (76.1%)Phase 3
12 (17.9%)Phase 2
3 (4.5%)Phase 4
1 (1.5%)A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
Phase 1
Not yet recruiting
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease PsychosisHallucinations and Delusions Associated With Parkinson Disease PsychosisNegative Symptoms of Schizophrenia
- Interventions
- Drug: LY03017-Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06980207
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Effect of Food and Age on the Pharmacokinetics of LY03017
Phase 1
Not yet recruiting
- Conditions
- Alzheimer's Disease PsychosisParkinson Disease PsychosisNegative Symptoms of Schizophrenia
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT06793995
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
Phase 1
Recruiting
- Conditions
- Tardive Dyskinesia (TD)
- Interventions
- Drug: LPM3770164 sustained release tablet 5 mgDrug: LPM3770164 sustained release tablet 10 mgDrug: LPM3770164 sustained release tablet 20 mgDrug: LPM3770164 sustained release tablet simulant
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06731868
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
Phase 1
Completed
- Conditions
- SchizophreniaAlzheimer's Disease Psychosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06556966
- Locations
- 🇨🇳
Beijing AnDing Hospital Capital Medical University, Beijing, China
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3
Recruiting
- Conditions
- Relapsed Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06496048
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Jilin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
No news found